What is the comprehensive pediatric and medical information on typhoid fever?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Typhoid Fever: Comprehensive Pediatric and Medical Overview

Clinical Presentation

Typhoid fever presents with fever as the universal symptom (100%), but contrary to traditional teaching, children under 5 years are significantly affected with an incidence rate of 27.3 per 1000 person-years—substantially higher than school-age children (11.7) or adults (1.1). 1 This challenges the outdated notion that typhoid primarily affects school-age children and adults.

Key Clinical Features by Frequency:

  • Fever: Universal presenting symptom (100%) 2
  • Cough: 47.9-57.1% of cases 2, 3
  • Altered bowel movements/diarrhea: 37-38% 2, 4
  • Abdominal pain: 19.8-27.1% 2, 4
  • Coated tongue: 21.7% 2
  • Vomiting: 20-23.8% 2, 4
  • Hepatosplenomegaly: 42.4% 4
  • Headache: 36% 4

Pediatric-Specific Considerations:

Children under 17 years present with fewer chills (7.1% vs 57.9% in adults) and more respiratory symptoms, though complications occur less frequently than in adults (14.3% vs 36.8%) 3. The morbidity in children under 5 years mirrors that of older patients in terms of fever duration, symptoms, and hospitalization needs 1.

Causative Organisms

  • Salmonella typhi: 80.5% of cases 2
  • Salmonella paratyphi A: 19.5% of cases 2
  • Paratyphoid B vaccines are ineffective and not recommended 5

Antimicrobial Resistance Patterns

The antibiotic landscape has dramatically shifted, with multidrug resistance (MDR) affecting 92.3% of strains in some regions, and emerging extensively drug-resistant (XDR) strains now classified as WHO Priority 2 pathogens. 4, 6

For S. typhi isolates (most effective to least):

  • Chloramphenicol: 98.9% sensitivity, 0% resistance 2
  • Azithromycin: 97% sensitivity, 0% resistance 2
  • Cotrimoxazole: 95.1% sensitivity 2
  • Meropenem: 94.3% sensitivity 2
  • Imipenem: 91.3% sensitivity 2
  • Levofloxacin: Only 67% sensitivity (33% resistant) 2
  • Ciprofloxacin: Only 61% sensitivity (39% resistant) 2
  • Ofloxacin: Only 48% sensitivity (52% resistant) 2

For S. paratyphi A isolates:

  • Meropenem: 89% sensitivity 2
  • Imipenem: 85.9% sensitivity 2
  • Chloramphenicol: 84.4% sensitivity 2
  • Cotrimoxazole: 79.7% sensitivity 2
  • Ciprofloxacin: Only 26.6% sensitivity (73.4% resistant) 2

Critical Caveat:

Reduced sensitivity to nalidixic acid in vitro correlates with clinical poor response to quinolone treatment 7. Eight of 31 strains (26%) showed reduced quinolone sensitivity in one pediatric series 7. All strains remain uniformly susceptible to gentamicin, amikacin, and furazolidone 4.

Vaccination Recommendations

Routine typhoid vaccination is NOT recommended in the United States, but selective vaccination is indicated for specific high-risk groups. 5

Indications for Vaccination:

  1. Travelers to endemic areas (Latin America, Asia, Africa) with prolonged exposure to potentially contaminated food/water
  2. Household contacts of documented typhoid carriers
  3. Microbiology laboratory workers frequently handling S. typhi
  4. Sewage workers only in endemic areas

Vaccination is NOT indicated for:

  • Rural summer camps
  • Natural disaster areas (floods)
  • Common-source outbreak control

Vaccine Options and Dosing:

For children ≥10 years and adults:

  • Oral Ty21a (live-attenuated): 4 enteric-coated capsules on alternate days with cool liquid (≤37°C), 1 hour before meals. Must refrigerate. Efficacy: 67% for ≥4 years 5
  • Parenteral inactivated: 0.5 mL subcutaneously, 2 doses ≥4 weeks apart. Efficacy: 51-76% 5

For children <10 years:

  • Oral Ty21a: Same 4-capsule regimen (limited experience <5 years) 5
  • Parenteral inactivated: 0.25 mL subcutaneously, 2 doses ≥4 weeks apart

Booster doses:

  • Parenteral vaccine: Every 3 years with continued exposure 5
  • Oral Ty21a: Manufacturer recommendations should be followed

Important Vaccination Caveats:

  • Vaccines are NOT 100% effective and can be overwhelmed by large inocula 5
  • Vaccination is NOT a substitute for careful food/water selection
  • Oral and parenteral vaccines have similar efficacy, but oral causes fewer adverse reactions 5
  • Only monovalent S. typhi vaccines should be used; TAB vaccines (including paratyphoid antigens) increase reactions without added benefit 5

Epidemiology

The highest incidence occurs in children 1-5 years (27.3 per 1000 person-years), with 44% of culture-positive cases in this age group in endemic areas. 1 This finding necessitates reassessment of optimal vaccination age, particularly given that most available vaccines have limited data for children under 5 years 5.

Most pediatric cases in non-endemic countries occur in second or third-generation immigrants from the Indian subcontinent visiting endemic regions 7. The majority come from lower socioeconomic classes with poor personal hygiene 4.

Diagnostic Approach

Blood culture before antibiotic administration is the gold standard and essential for diagnosis and appropriate treatment. 7 Only 53% of countries implement health facility-based surveillance with laboratory confirmation, and only 33% primarily use blood culture 8.

Perform antimicrobial susceptibility testing to guide therapy, as resistance patterns vary significantly by region 2, 4. The median hospitalization length is 7.5 days (range 5.0-10.3) 2.

Complications

Complications occur in 14.3% of pediatric patients and 36.8% of adults 3. Serious complications include:

  • Jaundice
  • Altered consciousness
  • Psoas abscess
  • Secondary hemophagocytic lymphohistiocytosis 9
  • Typhoidal anemia with bone marrow suppression 9

Mortality rate is approximately 2% in MDR cases 4, though overall mortality can reach 1% with protracted morbidity in survivors 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.